Science Explorer Back to mapMap
Discussion
Company · Charleroi · Belgium

Ogeda (Belgium)

ogeda.comROR OpenAlex
Research works
3
▼ 86% vs 2018-21
Citations
97
33.4 per fractional work
Top-10% rate
0.0%
all institutions 10.0%
Open access
71%
world 40%
International
77%
world 18%
Ogeda (Belgium)

Not ranked overall: Ogeda (Belgium) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Ogeda (Belgium) work in?

In all years, 55% of research at Ogeda (Belgium) is in Health Sciences, 45% in Life Sciences. Its largest fields are Medicine (55%), Biochemistry, Genetics and Molecular Biology (31%), Immunology and Microbiology (10%). It does 1.3× the world's share of Health Sciences.

Health Sciences: 2 fractional works · 55.2% of its workMedicine: 2 fractional works · 55.2% of its workLife Sciences: 1 fractional works · 44.8% of its workBiochemistry, Genetics and Molecular Biology: 1 fractional works · 31.0% of its workImmunology and Microbiology: 0 fractional works · 10.3% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 3.4% of its workALL ITS WORKOgeda (Belgium)3fractional works, all years
Life Sciences45%Health Sciences55%

Each ring splits the one inside it: the four domains of science, their fields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 2 domains and 4 fields, with their numbers
    1. Medicine255.2%
    1. Biochemistry, Genetics and Molecular Biology131.0%
    2. Immunology and Microbiology010.3%
    3. Pharmacology, Toxicology and Pharmaceutics03.4%
All of science, and how each field's share has moved since 1950: the Science domain explorer

What are the most cited papers from Ogeda (Belgium)?

The most cited paper from Ogeda (Belgium) is "Treatment of Menopausal Vasomotor Symptoms With Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial" (Herman T. Depypere, Dirk Timmerman, Gilbert G.G. Donders et al., 2019), with 153 citations. Next come "A natural ligand for the orphan receptor GPR15 modulates lymphocyte recruitment to epithelia" (97) and "Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary Syndrome" (56).

Most cited papers
#PaperReleasedCitations
1 Treatment of Menopausal Vasomotor Symptoms With Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial Herman T. Depypere, Dirk Timmerman, Gilbert G.G. Donders et al. · The Journal of Clinical Endocrinology & Metabolism Open access 15 Aug 2019 153
2 A natural ligand for the orphan receptor GPR15 modulates lymphocyte recruitment to epithelia Thomas Suply et al. · Science Signaling 12 Sep 2017 97
3 Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary Syndrome Graeme L. Fraser, Barbara Maria Obermayer-Pietsch, Joop S.E. Laven et al. · The Journal of Clinical Endocrinology & Metabolism Open access 17 May 2021 56
4 Assessment of a Urinary Kidney MicroRNA Panel as Potential Nephron Segment-Specific Biomarkers of Subacute Renal Toxicity in Preclinical Rat Models Stéphanie Glineur, Étienne Hanon, Sarah Dremier et al. · Toxicological Sciences Open access 28 Aug 2018 15
5 Clinical evaluation of the NK3 receptor antagonist fezolinetant (a.k.a. ESN364) for the treatment of menopausal hot flashes Herman T. Depypere, Dirk Timmerman, Gilbert G.G. Donders et al. · Maturitas Aug 2017 13
All 12 most cited papers, with filters and sorting

Which research topics does Ogeda (Belgium) publish most on?

By volume in 2022-now: Pharmacology and Obesity Treatment, Estrogen and related hormone effects, Menopause: Health Impacts and Treatments and Hormonal Regulation and Hypertension.

Pharmacology and Obesity Treatment: 0 fractional worksEstrogen and related hormone effects: 0 fractional worksMenopause: Health Impacts and Treatments: 0 fractional worksHormonal Regulation and Hypertension: 0 fractional worksPharmacogenetics and Drug Metabolism: 0 fractional worksHypothalamic control of reproductive hormones: 0 fractional works
PharmacologyGeneticsEndocrinology, Diabetes and MetabolismReproductive Medicine

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Pharmacology and Obesity Treatment Pharmacology 0 works
  2. 2 Estrogen and related hormone effects Genetics 0 works
  3. 3 Menopause: Health Impacts and Treatments Endocrinology, Diabetes and Metabolism 0 works
  4. 4 Hormonal Regulation and Hypertension Endocrinology, Diabetes and Metabolism 0 works
  5. 5 Pharmacogenetics and Drug Metabolism Pharmacology 0 works
  6. 6 Hypothalamic control of reproductive hormones Reproductive Medicine 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available71.3%not open28.7%

World: 40% of research is openly available.

with international co-authors77.0%domestic only23.0%

World: 18% is written across borders.

How has Ogeda (Belgium)'s research output changed?

Output in 2022-2025 was 86% lower than in 2018-2021.

still counting20202025

Other research institutions in Charleroi

All research institutions in Charleroi

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Ogeda (Belgium). Posts are plain text and can be reported.